Video

Dr. Beltran on the Significance of Genomic Sequencing in Prostate Cancer

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Himisha Beltran, MD, associate professor of medicine and physician in the Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology at Dana-Farber Cancer Institute and Harvard Medical School, discusses the significance of genomic sequencing in prostate cancer.

Not all men with prostate cancer will respond to PARP inhibitors; thus, the role of genomic sequencing has become increasingly important, says Beltran.

As such, the field of prostate cancer continues to enhance its knowledge of genomic sequencing in metastatic disease​, Beltran says.

Further refining genomic sequencing may provide insight into the role of DNA repair aberrations, the natural history of rare variants, the impact of co-occurring alterations, ​and the develop​ment of resistan​ce, Beltran adds.

Ultimately, harnessing genomic and non-genomic information will continue to play a critical role in treatment selectionfor men with prostate cancer, Beltran concludes.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic